ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ACTU vs KPTI // PIOTROSKI F-SCORE QUALITY

Actuate Therapeutics Inc. (NASDAQ) VS. Karyopharm Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ACTU 2 — KPTI 1
▲ PIOTROSKI F-SCORE QUALITY LEADER: ACTU
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACTU VS. KPTI) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ACTU KPTI SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 0.60% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality ACTIVE 3/9 2/9 +1.00 ACTU /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 34.7 51.4 -16.70 KPTI /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $20.4M $20.0M $449.7K ACTU /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ACTU REV KPTI REV ACTU GROSS % KPTI GROSS % ACTU FCF KPTI FCF
FY 2025 $0 $146.1M — — -$19.2M -$75.4M
FY 2024 $0 $145.2M — — -$21.8M -$127.6M
FY 2023 $0 $146.0M — — -$21.6M -$92.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACTU // BETA —
KPTI // BETA —